Merck to Acquire Peloton Therapeutics for $2.2B

 Merck to Acquire Peloton Therapeutics for $2.2B

Merck to Acquire Peloton Therapeutics for $2.2B

Shots:

  • Merck acquires Peloton, in all-stock transaction for $2.2B. Peloton to receive $1.05B cash as upfront & ~$1.15B as regulatory & commercial milestones for few candidates. The acquisition is expected to be close in Q3’19
  • The focus of the acquisition is to fortify Merck’s oncology portfolio with the addition of Peloton’s late-stage renal cell carcinoma candidate, PT2977
  • Peloton’s PT2977 is an oral HIF-2α inhibitor, currently being evaluated in multiple studies as a monothx. or in combination with cabozantinib for multiple indications

Click here to read full press release/ article | Ref: Merck | Image: Guide Post Solutions

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post